Veracyte (VCYT) Change in Accured Expenses (2016 - 2025)
Veracyte (VCYT) has disclosed Change in Accured Expenses for 14 consecutive years, with -$718000.0 as the latest value for Q4 2025.
- Quarterly Change in Accured Expenses fell 104.56% to -$718000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 78.37% year-over-year, with the annual reading at $6.3 million for FY2025, 78.37% up from the prior year.
- Change in Accured Expenses hit -$718000.0 in Q4 2025 for Veracyte, down from $9.1 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $12.9 million in Q2 2024 to a low of -$9.0 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $984300.0 across 5 years, with a median of $129000.0 in 2021.
- Biggest five-year swings in Change in Accured Expenses: plummeted 1879.74% in 2023 and later surged 45525.0% in 2025.
- Year by year, Change in Accured Expenses stood at $11.1 million in 2021, then tumbled by 81.02% to $2.1 million in 2022, then increased by 29.34% to $2.7 million in 2023, then plummeted by 112.89% to -$351000.0 in 2024, then tumbled by 104.56% to -$718000.0 in 2025.
- Business Quant data shows Change in Accured Expenses for VCYT at -$718000.0 in Q4 2025, $9.1 million in Q3 2025, and $6.8 million in Q2 2025.